.custom-column-left-text { float: left; width: 50%; padding-right: 10px; } .custom-column-right-text { float: right; width: 45%; text-align:center; } @media only screen and (max-width: 600px) { .custom-column-left-text, .custom-column-right-text, .custom-column-flc-ebook-text { float:none; width:80%; margin:0 auto; } }

Bioavailability Considerations

The formulation of an active pharmaceutical ingredient (API) to ensure maximum bioavailability is central to successful drug development.

Sickle Cell Disease News: Phase I Trial of Oral FTX-6058 to Promote Fetal Hemoglobin Set to Open

Business continuity, especially during times of uncertainty, is vital. Swift and decisive action to mitigate risk and support the ongoing viability of activities is crucial. The COVID-19 pandemic challenged the strongest, most actionable plans, and required support through consistent and clear communications.

Throughout the pandemic, Altasciences responded quickly and decisively with the goal of ensuring the safety of our teams, the animals in our care, and our study participants, as well as ensuring business continuity for our clients.

Using the most up-to-date medical and scientific information, we rapidly implemented new and adapted existing safety procedures in all areas of the business. We are proud and appreciative of the daily efforts of our teams and the resilience they showed during this time, which allowed us to maintain our operational capabilities and continue to fulfill client deliverables.

In Issue 15 of The Altascientist, we share how we kept operations running during the COVID-19 pandemic, highlighting:

  • employee health and safety
  • participant health and safety
  • animal welfare
  • travel restrictions and visitor screening
  • communication strategies
  • data and research integrity

 

 

Subscribe to